Central venous thrombosis and thrombophilia in cystic fibrosis: A prospective study  by Munck, Anne et al.
Original Articlewww.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 14 (2015) 97–103Central venous thrombosis and thrombophilia in cystic ﬁbrosis:
A prospective studyAnne Munck a,⁎, Ahmed Kheniche b, Corinne Alberti c, Dominique Hubert d,
Martine Reynaud-Gaubert e, Raphaele Nove-Josserand f, Isabelle Pin g, Francois Bremont h,
Raphael Chiron i, Laure Couderc j, Marie Laure Dalphin k, Estelle Darviot l, Bertrand Delaisi a,
Stéphane Dominique j, Isabelle Durieu f, Annelyse Fanton m, Michael Fayon n, Michèle Gérardin a,
Jean-Louis Giniès l, Charlotte Giraut o, Dominique Grenet p, Marcel Guillot q, Frédéric Huet m,
Muriel Le bourgeois r, Marlène Murris-Epin s, Sophie Ramel t, Anne Sardet u,
Isabelle Sermet-Gaudelus r, Françoise Varaigne v, Stéphanie Wanin w,
Laurence Weiss x, Marie-Francoise Hurtaud y
a Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Paediatric Gastroenterology and Respiratory Department, CF Centre, Université Paris 7, France
b Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Imaging Department, Université Paris 7, France
c Université Paris Diderot, Sorbonne Paris Cité, France; Inserm, CIE 5, Paris, France; Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Clinical
Epidemiology Unit, Paris, France
d Assistance publique-Hôpitaux de Paris, Hôpital Cochin, CF Centre, Université Paris Descartes, Sorbonne Paris Cité, France
e CF Centre, CHU Nord, Aix-Marseille Université, France
f Adult CF centre, Hospices Civils de Lyon, Groupe hospitalier Sud, Université de Lyon, France
g Pédiatrie, Pole Couple Enfants, CHU de Grenoble; INSERM U 823, Institut Albert Bonniot, Université Joseph Fournier, Grenoble, France
h CF centre, Hôpital d’enfants, Toulouse, France
i CF centre, Hôpital Arnaud de Villeneuve, Montpellier, France
j Department of Pneumology, Rouen University Hospital, France
k CF centre, Hopital Jean Minjoz, Besançon, France
l CF centre, Hôpital d’ Angers, France
m CF centre, Hôpital d’enfants du Bocage, Dijon, France
n CF centre, Hopital Pellegrin CIC 005, CHU Bordeaux, France
o CF centre, Hôpital de Clocheville, Tours, France
p CF centre, Hôpital Foch, Suresnes, France
q CF centre, Hôpital Robert Bisson, Lisieux, France
r Assistance publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, CF centre, University Paris 5, France
s CF centre, Hôpital Larrey, Toulouse, France
t CF centre, Centre Perharidy, Roscoff, France
u CF centre, Hôpital de Lens, France
v CF centre, Hôpital Bretonneau, Tours, France
w Hospices Civils de Lyon, Hopital Femme-Mère-Enfant, CF centre, Bron, France
x CF centre, Hôpital de Hautepierre, Strasbourg, France
y Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Biological Hematology Department, Université Paris 7, France
Received 14 March 2014; received in revised form 20 May 2014; accepted 20 May 2014
Available online 5 August 2014Abbreviations: CF, cystic fibrosis; TIVAD, totally implantable vascular access device.
⁎ Corresponding author at: Assistance publique-Hôpitaux de Paris, Hôpital Robert Debré, Paediatric Gastroenterology and Respiratory Department, CF Centre,
Université Paris 7, France 48, boulevard SERURIER 75019 Paris, France. Tel.: +33 1 40 03 47 54; fax: +33 40 03 47 55.
E-mail address: anne.munck@rdb.aphp.fr (A. Munck).
http://dx.doi.org/10.1016/j.jcf.2014.05.015
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
98 A. Munck et al. / Journal of Cystic Fibrosis 14 (2015) 97–103AbstractBackground and Aims: Catheter venous thrombosis may result in life-threatening embolic complications. Recently, a thrombophilic tendency was
described in cystic ﬁbrosis (CF), the signiﬁcance of which remains unclear. The aims of this study were to (1) document the frequency of catheter
venous thrombosis detected by colour-Doppler-ultrasound (Doppler-US), (2) assess genetic and acquired thrombophilia risk factors for catheter
venous thrombosis and hypercoagulability status and (3) provide recommendations on laboratory screening when considering insertion of a totally
implantable vascular access device (TIVAD) in CF patients.
Methods: We designed a multicentre prospective study in patients selected at the time of catheter insertion. Doppler-US was scheduled at 1 and
6 months after insertion and before insertion in case of a previous central line. Blood samplings were drawn at insertion and at 1 and 6 months
later.
Results: One-hundred patients received a TIVAD and 90 completed the 6-month study. Prevalence of thrombophilia abnormalities and
hypercoagulability was found in 50% of the cohorts. Conversely, catheter venous thrombosis frequency was low (6.6%).
Conclusion: Our data do not support biological screening at the time of a TIVAD insertion. We emphasise the contribution of a medical history of
venous thromboembolism and prospective Doppler-US for identifying asymptomatic catheter venous thrombosis to select patients who may
beneﬁt from biological screening and possible anticoagulant therapy.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Thrombosis; Thrombophilia1. Introduction
Respiratory degradation, closely related to recurrent pulmo-
nary infections, remains the main cause of morbidity and mor-
tality in patients with cystic fibrosis (CF). Thus, patients must
undergo frequent antibiotic treatments that – depending on the
pathogen involved – are often delivered intravenously. Increas-
ing problems with peripheral venous access may indicate im-
plantation of central venous access devices. Totally implantable
vascular devices (TIVADs) were initially introduced in clinical
oncology practice [1] and, more recently, in CF patients [2].
They are usually well tolerated for long periods. Nevertheless,
they may be associated with numerous complications [3] and, in
large retrospective studies, symptomatic catheter venous throm-
bosis rates ranged from 3.5% to 16.4% [4,5] with clinical reports
of pulmonary embolism [6].
The thrombogenic role of the indwelling catheter has been
studied mainly in cancer patients. In these patients, the inci-
dence of clinically symptomatic deep venous thrombosis has
been reported in up to 9.3 % of adults [7] and 14% of paediatric
cohorts [8]. In prospective studies, the incidence of catheter
venous thrombosis detected through venography was 58% in
adults [9] and 50% in children [10] in small cohorts. Verso et al.
[11] reported the main pathogenic factors for TIVAD-catheter
venous thrombosis: vessel injury caused by the procedure of
insertion, venous stasis and catheter tip position, previous
TIVAD, catheter infections, cancer-related hypercoagulability
and thrombophilic molecular abnormalities. Concerning the
delay in catheter venous thrombosis occurrence after TIVAD
insertion and detection by Doppler-ultrasound (Doppler-US),
two prospective studies in cancer patients found that catheter
venous thrombosis was an early complication, occurring be-
tween 8 and 30 days [12] or after a mean delay of 42 days [13].
CF population is distinct from cancer cohorts, but these data
contributed to establishing our flow chart study with the du-
ration of follow-up of 6 months after TIVAD insertion.
Recently, a thrombophilic tendency has been reported in the
CF population [14–18], the significance of which remains unclear.Some authors have thus recommended including thrombophilia
screening prior to catheter insertion for all CF patients [14,15].
A better understanding of thrombophilic risk factors for
catheter venous thrombosis in CF patients with a TIVAD may
contribute to the implementation of preventive screening strat-
egies. Prophylaxis with low-molecular-weight heparin or a low
fixed dose of warfarin has been proposed although studies do
not enable definitive recommendations. Hence, we conducted a
prospective multicentre study in patients with CF to document the
frequency of catheter venous thrombosis detected by Doppler-
US as defined by Verso [11], to screen genetic and acquired
thrombophilic risk factors for catheter venous thrombosis and
hypercoagulability status and to provide recommendations when
a TIVAD is planned.
1.1. Patients and methods
We conducted a prospective study in 41 paediatric and
adult CF centres that agreed to participate. Patients who were
regularly followed up at one of these centres received compre-
hensive information on the study when TIVAD insertion was
planned. The study was approved by the ethical committee
IRB APHP, N° CCP0511153 and was registered on www.
clinicaltrials.gov: NCT 00244270. Written informed consent
form was obtained from all adults or from both parents of
children at inclusion (initial visit). Blood sample (12 mL) was
drawn and analysed locally within 4 h. C-reactive protein
(N15 mg/L) and fibrinogen (N4.5 g/L) served as markers of
inflammatory activity. Prothrombin time (reference value
N80%) was chosen as a global test of coagulation to assess
liver function and vitamin K status. Thrombophilia screening
included: (i) genetic factors: protein C and protein S abnormal
if ≤70% and ≤60%, respectively, in the absence of inflam-
matory markers and vitamin K deficiency [19,20], antithrom-
bin abnormal if b79% in the absence of cirrhosis [19],
identification of factor II G20210A gene mutation or factor V
Leiden mutation; (ii) acquired factors: cardiolipin antibodies
tested by enzyme-linked immunosorbent assay (ELISA) (IgG
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markers). Hypercoagulability status was defined by increased
D-dimers N530 ng/ml. We defined three groups of patients:
subjects presenting thrombophilic abnormalities (group A),
hypercoagulability status (group B) and no identified abnor-
mality (group C). At initial visit, a Doppler-US was performed
prior to TIVAD insertion in case of previous central lines.
Vessel exploration performed on the body side of previous
TIVAD insertion included jugular, axillary and subclavian,
innominate and superior caval veins. The main criteria for
establishing the diagnosis of catheter venous thrombosis on
initial visit Doppler-US were visualisation of mural thrombi or
incompressibility of veins, absence of spontaneous flow or
presence of turbulent blood flow, absence of transmission of
cardiac pulsatility and visualisation of increased venous col-
laterals [11]. In case of difficult diagnostic situations, accord-
ing to the current practice in each centre, contrast venography
or magnetic resonance was performed. The following data
were collected at the time of TIVAD insertion: demographic
data, cystic fibrosis transmembrane conductance regulator
(CFTR) genotype, personal and first-degree relative thrombo-
embolism history, co-morbidity factors (CF-related diabetes
(CFRD), cirrhosis), patient’s weight and height to calculate
body mass index (BMI), z score in children and absolute
values in adults [22], most recent data on lung function (forced
expiratory volume in 1 s (FEV1)) using published reference
ranges in children and adults [23,24] and sputum microbiol-
ogy status. Concerning the TIVAD procedure, data were col-
lected on the operator (anaesthetist or surgeon), location of the
catheterised vessel, modality of catheter insertion (denudation
or puncture), catheter material (polyurethane, silicone), blood
sampling through the catheter and maintenance of TIVAD
current practice in the CF centre (none, counterpressure, regular
heparin). At insertion, a chest X-ray was performed to confirm
the correct position of the distal extremity of the catheter. One
month (follow-up visit 1: 30–45 days) and 6 months later
(follow-up visit 2: 6 months ± 15 days), the patient had a com-
plete re-evaluation, including data on TIVAD complications,
Doppler-US, blood sampling for acquired thrombophilia factors
and hypercoagulability profile. A second chest X-ray was per-
formed at the end of the study to re-evaluate the catheter tip
position.
In case of clinical symptoms of catheter venous thrombosis,
the patient was asked to come immediately to the CF centre for
a complete assessment.1.2. Statistical analysis
Qualitative variables were described as numbers and/or
percentages and quantitative variables as medians with their
quartiles (Q1–Q3). Differences were tested by the chi-square
test and Fischer’s exact test to compare proportions across
categories and by non-parametric Kruskal–Wallis’s test for
quantitative variables. Statistical analyses were performed with
SAS 9.3 (Cary, NC, USA) software for PC computer. All tests
were bilateral and statistical significance was set at p b 0.05.2. Results
2.1. Study population
Initial visits involved 104 patients, who were regularly
followed at 28 CF centres that recruited 1 to 20 patients per
centre. Informed consent withdrawal signatures occurred in
three cases before TIVAD insertion. At the time of TIVAD
insertion, one patient with an uncontrolled catheter infection
could not be recruited. Thus, 100 patients underwent TIVAD
insertion between January 2006 andMarch 2009. They included
65 adults and 35 children, 60 females and 40 males, with a
median age of 19.8 (15.5–27.2) years. The genotype was
F508del/F508del in 44%, F508del/other in 42% and unknown
for at least one allele in 15%. Ninety patients completed the
6-month study (two deaths related to pulmonary deterioration,
one consent withdrawal, three TIVAD removals (lung trans-
plantation, catheter occlusion and palpitations) and, lastly, four
patients who did not undergo Doppler-US at the second follow-
up visit).2.2. Doppler-US and catheter venous thrombosis identification
Among the 44 patients who had had a previous central line, a
Doppler-US was performed prior to TIVAD insertion at initial
visit and a catheter venous thrombosis was identified in four (4/
44, 9.1%). Radiographic images were consistent with sequelae
of long-standing obstruction including vessel collateralisation,
organised thrombus and parietal thickness. In one patient, diag-
nosis of catheter venous thrombosis had to be confirmed by
magnetic resonance.
Then during the 6-month study, a catheter venous thrombosis
was reported in two additional patients. One was symptomatic
with neck pain at the first follow-up visit, while the other,
asymptomatic, was diagnosed at the second follow-up visit. In
the first patient, Doppler-US showed a localised occluded right
jugular vein with dilatation of the external and anterior jugular
veins without collateralisation; in the second patient, it showed
extensive thrombus partially occluding the innominate vein with
stasis but no collateralisation. Hence, the frequency of catheter
venous thrombosis diagnosed based on symptoms or detected
by Doppler-US was 6/90 (6.6%).2.3. Thrombophilia and hypercoagulability abnormalities
Thrombophilia screening for inherited and acquired risk
factors for catheter venous thrombosis identified abnormalities
in up to 17/100 (17%) patients (Table 1). These abnormalities
included protein C deficiency (1/100, 1%), protein S deficiency
(3/100, 3%), antithrombin deficiency (2/100, 2%), factor V
Leiden heterozygosity (4/100, 4%), prothrombin G20210A
heterozygosity (2/100, 2%) and combined abnormalities in three
patients (3%). None of the patients carrying low values of
antithrombin, protein C or protein S presented liver disease,
vitamin K deficiency or increased inflammatory markers.
Increased IgG anticardiolipin was found for two patients (2%).
Table 1
Thrombophilia and HC rates (%) in 100 CF patients carrying a TIVAD and
expected abnormality rates in a healthy population [26,27].
CF
abnormality
rate (%)
Expected
abnormality
rate in healthy
population
(%) [26,27]
Thrombophilia abnormalities 17
Inherited
Protein C deficiency, N(%) 1(1) (0.2–0.4)
Protein S deficiency, N(%) 3(3) (0.13–0.3)
Antithrombin deficiency, N(%) 2(2) (0.02–0.16)
Factor V Leiden mutation, N(%) 4(4) (4.8)
Prothrombin G20210A mutation, N(%) 2(2) (2)
Protein C deficiency + factor V Leiden
mutation, N(%)
1(1) Unknown
Protein S deficiency + antithrombin
deficiency, N(%)
1(1) Unknown
Double heterozygosity prothrombin
G20210A + factor V Leiden, N(%)
1(1) (0.01)
Acquired
Ig G anticardiolipin increased, N(%) 2(2) Unknown
Hypercoagulability 38(38)
Increase in D-dimers, N(%) 38(38) Unknown
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were found in 38 (38%) patients. Five patients had both
thrombophilic and hypercoagulability risk factors for catheter
venous thrombosis.
Data on age, lung function, nutritional status, medical history
of thromboembolism, modalities of TIVAD insertion and
maintenance were not different in the three groups. Likewise,
the prevalence of inflammatory markers (e.g., C-reactive protein,
fibrinogen), CF co-morbidity factors, respiratory colonisationTable 2
Demographic data, acquired risk factors for CVT in CF patients carrying a TIVAD:
TB or HC abnormalities).
Total n = 100 Group A (n =
Age (y) 22.9 [15.7; 28
FEV1 % b18y 46.2 [27.7; 88
≥18y 35.4 [26.3; 52
Median BMI b18y (z-score) -1.0 [-1.5;-0.9]
≥18y 19.2 [17.6; 20
Thromboembolism history, personal or first-degree, N (%) 4(24)
Median C-reactive protein (mg/L) 10 [6,16]
Median fibrinogen (g/L) 4.2 [3.5; 5.6]
Cirrhosis, N (%) 2(12)
Diabetes, N (%) 6(35)
Pseudomonas aeruginosa, N (%) 15(88)
Burkholderia cepacia, N (%) 0
Oral contraceptives, N (%) 3/10(30)
Previous catheter, N (%) 10(59)
Vessel: jugular/subclavian (%) 63/13
Catheter material (%): polyurethane/silicone 19/81
Blood sampling, N (%) 1(6)
TIVAD maintenance, N (%) 6(35)
# Chi 2 test.
⁎ Fisher’s exact test.
+ Kruskal–Willis test.with Pseudomonas aeruginosa, Burkholderia cepacia, oral
contraceptives and previous central catheter (Table 2) was also
not different.
2.4. Description of patients with central venous thrombosis
Six patients presented catheter venous thrombosis (Table 3).
In asymptomatic patients, five cases of catheter venous throm-
bosis was detected by Doppler-US. In four cases (two adults and
two adolescents), catheter venous thrombosis was found at
initial Doppler-US performed because of a previous central line
(n = 44). A previous history of catheter venous thrombosis was
identified in two patients. Inherited thrombophilia abnormalities
were present in both adults (antithrombin deficiency, double
heterozygosity factor V Leiden + prothrombin G20210A); the
female patient had combined hypercoagulability status with
other risk factors (diabetes, oral contraceptive use). Conversely,
both children had normal thrombophilia profiles; the male
adolescent had very severe cirrhosis with hypercoagulability
status. For all four patients, subsequent TIVAD had to be
inserted in the contralateral catheter venous thrombosis body
side. Long-term anticoagulant therapy was prescribed in both
adults, in agreement with the local haematology team. Neither
of the two adolescents was started on anticoagulant therapy,
because of an increased bleeding risk related to severe liver
disease in the male and because of normal thrombophilic and
hypercoagulability profiles in the female. All four patients had
an uneventful clinical course, with normal Doppler-US explo-
ration during the entire prospective study period. Three cases
remained clinically asymptomatic for 29–40 months but the
fourth patient died several weeks after the second follow-up
visit from end-stage cirrhosis.
During the study period, catheter venous thrombosis was
identified in two other adults, one at the first follow-up visitgroup A (TB abnormalities), group B (HC abnormalities) and group C (without
17) Group B (n = 33) Group C (n = 50) p-value
.1] 22.2 [17.1; 28.2] 19.1 [14.3; 26.2] 0.42 +
.7] 68.2 [41.1; 95.0] 57.2 [51.4; 75.1] 0.84 +
.8] 35.8 [27.4; 50.4] 37.0 [23.0; 52.2] N .99 +
-1.2 [-2.1; 0.7] -1.1 [-1.6; 0.1] 0.91 +
.6] 18.8 [17.6; 19.9] 18.9 [17.9; 20.7] 0.83 +
5(16) 3(6) 0.11 ⁎
23 [10; 52] 13 [5,31] 0.10 +
5.0 [4.4; 5.9] 4.2 [3.5; 5.6] 0.06 +
4(12) 5(10) N .99 ⁎
8(24) 15(30) 0.70 #
27(82) 37(94) 0.24 ⁎
1(3) 5(12) 0.31 ⁎
8/19(42) 8/30(27) 0.52 #
11(34) 24(48) 0.23 #
58/26 50/37 0.39 ⁎
25/75 35/65 0.37 #
1(3) 4(9) 0.85 ⁎
9(26) 24(44) 0.27 #
Table 3
Description of patients with CVT.
Age (y), sex (M, F) 25.2, M 23, F 17, M 14.4, F 24.6, M 27.2, M
Time at CVT diagnosis (initial, follow-up 1, follow-up 2) initial initial initial initial follow-up 1 follow-up 2
Asymptomatic (A) or symptomatic (S) A A A A S A
Number of previous central catheters 2 2 1 5 1 0
Personal or first-degree relative history of venous thrombosis + − + − − −
Inherited TB abnormalities + + − − − −
Increased D-dimers − + + − + −
Cirrhosis − − + − − +
Diabetes − + − − − −
Oral contraceptives NA ⁎ + NA NA NA NA
Burkholderia cepacia − − − − − −
Catheter material: polyurethane/silicone S S S P P P
Anticoagulant therapy + + − − + +
TIVAD removal No No No No No No
Clinical follow-up (months) 30 29 28 40 31 17
⁎ NA: not applicable.
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visit with cirrhosis as a risk factor for catheter venous
thrombosis. None of these two adults presented abnormal
thrombophilia profiles and their C-reactive protein concentra-
tions were 27 and 12 mg/L. TIVADs were not removed and
both patients received long-term anticoagulant therapy with
clinical uneventful follow-up, thereby preventing catheter
venous thrombosis recurrence.
3. Discussion
To our knowledge, this is the first prospective multicentre
analysis to evaluate the frequency of catheter venous thrombosis
and to study markers of thrombophilic and hypercoagulability
status in CF patients carrying a TIVAD. We studied a large
cohort of 100 patients who had been screened via a standardised
panel of thrombophilia risk factors. Catheter venous thrombosis
detection by Doppler-US was performed prospectively and
longitudinally. We found a very high rate of thrombophilia and
hypercoagulability status, attaining 50%, but a very low fre-
quency of catheter venous thrombosis (6/90, 6.6%). Rates of
catheter venous thrombosis were close to this value in adult (4/
65, 6.1%) and paediatric patients (2/35, 5.7%). We may have
underestimated the prevalence of asymptomatic catheter venous
thrombosis by Doppler-US detection, compared with contrast
venography, which is considered ‘the gold standard’ in de-
tecting catheter venous thrombosis. However, repeated proce-
dures of this technique are not applicable for surveillance
because of invasiveness and cost [11]. Reported data regarding
the diagnostic value of colour-Doppler-US compared with
venography demonstrated excellent sensitivity and specific-
ity for diagnosis of catheter venous thrombosis in axillary-
subclavian veins (95%) and jugular veins (100%) [24] but were
less reliable for innominate and superior caval veins [25]. To
minimise variability in Doppler-US analysis, a referring ra-
diologist was designated at each CF centre. As regards the low
incidence of catheter venous thrombosis, our study enabled only
a descriptive analysis of data, hampering statistical analysis of
catheter venous thrombosis risk factors.Inherited thrombophilia factors for venous thrombosis in
adults [26] and children [27] fall mainly into two categories:
hereditary antithrombin, protein C or S deficiencies, and factor
V Leiden or prothrombin G20210A mutations. We found an
unusually high prevalence of these abnormalities compared to
healthy populations [26,27], but this was in agreement with
previous publications on thrombophilia in CF [14–17]. In our
study, the laboratory thrombophilic panel did not assess factors
identified as hypothetic risk factors for thrombosis in the
general population and possibly in CF patients such a rise in
factor VIII [16] or hyperhomocysteinaemia. Given the current
state of our knowledge, the significance of these abnormalities
remains questionable [28].
Previous retrospective studies in CF reported clinically
symptomatic catheter venous thrombosis rates varying from
3.5% [4] to 16.4% [5]. In asymptomatic oncology patients,
venographic catheter venous thrombosis incidence reached
50% of adult and paediatric cohorts [9,10]. None of those
studies evaluated thrombophilic risk factors for catheter venous
thrombosis.
If we consider the 41 CF patients reported in the literature
(Table 4) carrying a TIVAD and who were evaluated for a
variety of heterogeneous thrombophilic risk factors, symptom-
atic catheter venous thrombosis was identified in four cases
(9.7%) and thrombophilic abnormality was identified in two of
these (50%); by contrast, the prevalence of thrombophilia was
16% (6/37) in patients who did not present symptomatic catheter
venous thrombosis. However, considering the small number of
patients included, the diversity of thrombophilic factors eval-
uated in those three cohorts and detection of symptomatic
catheter venous thrombosis only, these data do not enable de-
finitive conclusions or a comparison with our study.
The incidence of inherited thrombophilic abnormalities in
the healthy population is low, ranging from 0.2% for anti-
thrombin deficiency to 4.8% for factor V Leiden. The signif-
icance of inherited thrombophilia, acquired thrombophilia
abnormalities and hypercoagulability status is not clear, as it
is widely recognised that many individuals who carry these
defects remain asymptomatic. Furthermore, at least 50% of
Table 4
Previous studies on thrombophilia markers in CF patients carrying a TIVAD.
Patients (n)/age range Barker [14]2005
(66); 3–38 y
Balfour-Lynn [15] 2005
(204); 1–17 y
Williams [18] 2010
(71); 1–11 y
Protein C deficiency 20% 4% 14%
Protein S deficiency 30% 5% 20%
Antithrombin deficiency ND 1% 0%
Prothrombin G20210 mutation 1.5% ND ND
Factor V Leiden mutation 9% 5% 4.2%
Anticardiolipin 9.5% 9% 18%
Patients with TIVAD (n) 16 15 10
thrombophilia (%) 0 27 22
Patients with TIVAD and CVT (n) 4 0 0
factor V Leiden mutation (%) 50 - -
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[30]. Venous thromboembolism is a multifactor disease and
may result from the simultaneous conjunction of several genetic
or acquired risk factors. It has been reported that, in the absence
of other acquired risk factors, the relative risk of thrombo-
embolism for factor V Leiden varies from 3.7 to 7.9 and for
prothrombin G20210 from 1.9 to 2.8 [31]. However, the
importance of detecting thrombophilic abnormalities is sup-
ported by the increased risk of venous thromboembolism,
especially in the presence of additional risk factors such as
factor VIII [16] or activated platelets [17] (though many affected
individuals remain asymptomatic). It is generally accepted, at
least in adults [27], that antithrombin deficiency, associated
inherited thrombophilia factors and homozygosity for factor V
Leiden represent the most severe relative risk factors for
recurrent venous thrombosis, well ahead of protein S or C
deficiencies [29]. The role of these abnormalities in childhood
thrombosis has not yet been established [32].
A potential weakness of this study is that inherited
thrombophilic abnormalities were not retested, because this
was not scheduled in the protocol. This control, which separates
congenital from acquired or possibly temporary risk factors for
thrombophilia, enables avoiding mislabelling of patients as
thrombophilic. In the literature involving CF patients, Balfour-
Lynn et al. [15] found a thrombotic abnormality in 41/204
(20%) patients, which persisted after resampling in 37/38.
Barker et al. [14] identified a thrombophilic state in 53% of 66
patients; when retesting after a mean period of 3 years, they
confirmed protein S deficiency in 86%, but protein C and
anticardiolipin antibodies demonstrated poor reproducibility.
Williams et al. [18], in a CF paediatric cohort, demonstrated
10–20% consistency for protein S and C deficiencies.
Because many other acquired factors [11], in addition to
the presence of the indwelling catheter [33], may promote
thrombophilia and possibly catheter venous thrombosis, we
collected data on personal and first-degree relative history of
thromboembolism, oral contraceptives use and those most
relevant to CF: cirrhosis, diabetes, Pseudomonas aeruginosa
and Burkholderia cepacia infections. We found an equal
prevalence of these factors in the three studied groups.
More specifically, among the 12 subjects having a personal
or first-degree relative history of venous thrombosis and who
have been screened for thrombophilia and hypercoagulabilitystatus, a thrombophilia profile was identified in 75% (9/12).
Among them, two patients had asymptomatic catheter venous
thrombosis diagnosed during our study (22%). It is crucial to
collect a comprehensive medical history on previous venous
thrombosis, thus enabling selection of patients who will benefit
from biological screening.
Recently, Raffini et al. [34] reported increased risk of catheter
venous thrombosis in CF patients carrying Burkholderia cepacia
(27% vs. 3.7%). This organism, identified in 7% of our entire
cohort, was not carried among those presenting a catheter venous
thrombosis.
We confirmed an increased incidence of thrombophilia
abnormalities in our cohort, in agreement with previous reports
in CF subjects. The consistency between these recent reports
suggests that, rather than inherited thrombophilia, there may be
a common underlying predisposing factor such as systemic
inflammation that in combination with other factors may be
responsible. Although thrombophilia abnormalities appear to
be a true risk factor for thrombosis in CF patients, the clinical
benefit of screening patients as a prelude to catheter or TIVAD
insertion remains a subject of debate.
Despite a high incidence of prothrombotic and hypercoag-
ulability risk factors, our prospective study involving a large
cohort demonstrated a low prevalence of catheter venous
thrombosis. Laboratory thrombophilia screening had contrib-
uted little and was poorly predictive for those presenting a
catheter venous thrombosis. Thus, in contrast to some authors
and based on our data, we cannot recommend including
thrombophilic screening prior to catheter insertion for all CF
patients. We emphasise the contribution of a medical history of
venous thromboembolism and of prospective Doppler-US for
all patients carrying a catheter for identifying asymptomatic
catheter venous thrombosis, in order to select those who will
undergo biological screening. Subsequently, for those present-
ing positive thromboembolism or biological abnormalities, or a
catheter venous thrombosis, the modalities of therapeutic anti-
coagulation and contraceptive counselling will be defined in
cooperation with the haematology department. A better under-
standing of the role of thrombophilia risk factors for catheter
venous thrombosis can be clarified only by comparing the
prospective incidence of thrombosis between patients with
and without indexes of thrombophilia in larger studies. This
will hopefully enable caregivers to make a more accurate
103A. Munck et al. / Journal of Cystic Fibrosis 14 (2015) 97–103evidence-based assessment for the benefit of individual
patients.
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